May 31, 2017
1 min read

Hydroxychloroquine not linked with hemolytic anemia in patients with G6PD deficiency

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Among glucose-6-phosphate dehydrogenase-deficient patients with rheumatic disease, hydroxychloroquine was not linked with hemolytic anemia, according to a recently published analysis.

Samya Mohammad, DO, from Duke University Medical Center, and colleagues reviewed 275 patients, of which 32% had lupus; 29% had rheumatoid arthritis; 14% had inflammatory arthritis; and 4% were glucose-6-phosphate dehydrogenase (G6PD)-deficient. Overall, nearly half of the patients in the study (46%) were African American and all patients with G6PD-deficiency were African American.

Only two G6PD-deficient patients had hemolysis while not undergoing hydroxychloroquine therapy. In addition, there were no hemolysis episodes in the 11 G6PD-deficient patients.

Researchers reported this was the largest United States study of G6PD deficiency in patients undergoing hydroxychloroquine for rheumatic disease. – by Will A. Offit

Disclosure : Researchers report no relevant financial disclosures.